摘要
目的比较两种不同新辅助化疗方案治疗进展期乳腺癌的疗效。方法1999年9月～2004年9月用CF、FAC方案新辅助化疗治疗Ⅱ、Ⅲ期乳腺癌30例。CF方案:甲酰四氢叶酸钙(CF)300mg/d,第1～5天,持续4h静脉滴注,氟尿嘧啶(5-FU)500mg/d,第1～5天,持续4h静脉滴注,4周为1个周期;FAC方案:5-FU500mg/d,第1、第8日,持续4h静脉滴注,阿霉素(ADM)40mg/m2,第1天静脉注射,环磷酰胺(CTX)500mg/m2,第1、第8天静脉注射,4周为1个周期。均完成2个周期后评价疗效。结果CF组总有效率为66.7%(10/15),其中临床完全缓解(CCR)1例,部分缓解(PR)9例,无变化(NC)5例。FAC组总有效率为40%(6/15),其中CCR1例,PR5例,NC9例。两组中Ⅱ期疗效高于Ⅲ期,CF方案组与FAC方案组疗效比较有统计学差异(P<0.05)。结论两组新辅助化疗方案对乳腺癌均有效,毒副反应均可耐受,CF组疗效高于FAC组。
Objective\ To compare the efficacy of two different regimens as neoadjuvant chemotherapy for breast cancer in progress stage. Methods Thirty patients with stage Ⅱ and Ⅲ breast cancer were treated with either calcium folinate (CF) and 5-fluorouracil (5-FU ) or 5-FU,adriamycin(ADM), and cyclophosphamide(CTX) regimens for 2 cycles every four weeks. Clinical responses were assessed after 2 cycles of neoadjuvant chemotherapy. Patients in CF scheme received 5-FU 500 mg/d by 4 hours continuous infusion from day 1 to day 5, CF 300 mg/d by 4 hours continuous infusion from day 1 to day 5. Patients assigned to the FAC scheme received 5-FU 500 mg/d by 4 hours continuous infusion on day 1 and day 8, ADM 40 mg/m^2 by intravenous injection on day 1, CTX 500 mg/m^2 by intravenous injection on day 1 and day 8. Results For advanced breast cancer, the overall response rate was 66.7%(10/15) in CF scheme and 40.0%(6/15) in FAC scheme. Patient showed clinical complete response in 1, partial response in 9 and no change in 5 after the CF schems therapy, while patient showed complete response in 1, partial response in 5 and no change in 9 after FAC scheme therapy. A proportion of response rate in stage Ⅱ was higher than that of stage Ⅲ. The efficacy in CF group was significantly higher than that of FAC group (P<0.05) Conclusions Neoadjuvant chemotherapy is effective to advanced breast cancer, and the side effects and toxicity is tolerable. The efficacy in CF scheme is better than that of FAC scheme.
关键词
化疗
治疗
乳腺癌
比较研究
CF方案
FAC方案
Breast carcinoma
5-fluorouracil
Adriamycin
Calcium folinate
Cyclophosphamide
Neoadjuvant chemotherapy
